This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Osiris Therapeutics Inc
OSIR : NASDAQ : Health Care
$10.28 -0.18 | -1.72%
Today's Range: 10.24 - 10.57
Avg. Daily Volume: 250,400
11/25/15 - 4:00 PM ET

Financial Analysis

OSIRIS THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2015 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. OSIRIS THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 4.53 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 1.45% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q3 FY15 Q3 FY14
Net Sales ($mil)24.2917.2
EBITDA ($mil)0.191.46
EBIT ($mil)-0.121.22
Net Income ($mil)-0.840.65

Balance Sheet Q3 FY15 Q3 FY14
Cash & Equiv. ($mil)43.3458.36
Total Assets ($mil)102.3591.71
Total Debt ($mil)0.050.05
Equity ($mil)80.9282.12

Profitability Q3 FY15 Q3 FY14
Gross Profit Margin0.768.5
EBITDA Margin0.768.5
Operating Margin-0.497.09
Sales Turnover0.860.53
Return on Assets2.4551.46
Return on Equity3.430.18
Debt Q3 FY15 Q3 FY14
Current Ratio5.439.61
Interest Expense0.00.0
Interest Coverage0.00.0

Share Data Q3 FY15 Q3 FY14
Shares outstanding (mil)34.4534.32
Div / share0.00.0
Book value / share2.352.39
Institutional Own % n/a n/a
Avg Daily Volume242907.0183979.0


HOLD. OSIRIS THERAPEUTICS INC's P/E ratio indicates a significant premium compared to an average of 47.43 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 21.93. To use another comparison, its price-to-book ratio of 4.50 indicates a significant premium versus the S&P 500 average of 2.77 and a significant discount versus the industry average of 16.75. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
OSIR 132.13 Peers 47.43   OSIR 43.50 Peers 42.69

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

OSIR is trading at a significant premium to its peers.


Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

OSIR is trading at a valuation on par to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
OSIR 84.56 Peers 19.59   OSIR NM Peers 0.56

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

OSIR is trading at a significant premium to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

OSIR's negative PEG ratio makes this valuation measure meaningless.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
OSIR 4.50 Peers 16.75   OSIR NA Peers 14.89

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

OSIR is trading at a significant discount to its peers.


Neutral. Higher earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

The growth rate for OSIR is not available.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
OSIR 4.12 Peers 289.74   OSIR 81.57 Peers 60.69

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

OSIR is trading at a significant discount to its industry on this measurement.


Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

OSIR has a sales growth rate that significantly exceeds its peers.



Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums

Latest Stock Upgrades/Downgrades

Top Rated Stocks Top Rated Funds Top Rated ETFs